PLoS One
Animal Models in Metastatic Breast Cancer Immunotherapy Research
Mirzaei Y, Hüffel M, McCann S, Bannach-Brown A, Tolba RH, Steitz J.
In this systematic review and meta-analysis, the authors evaluated the impact of immunotherapy on regression of primary and metastatic tumors in animal models of metastatic breast cancer. They also determined the appropriateness and reproducibility of the models to improve future preclinical study design.
Previous Article
- • Delphi Consensus for Managing Adverse Events in Patients With Metastatic Triple-Negative Breast Cancer Receiving Sacituzumab Govitecan
- • The Safety and Effectiveness of Palbociclib in Clinical Practice
- • Determinants of HER2-Targeted Therapy Use in Metastatic HR-/HER2+ Breast Cancer
- • Equity of Care Across Metastatic Breast Cancer Treatment
- • Tumor Growth Rate and Survival in Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
- • Patient-Reported Outcomes From DESTINY-Breast04
- • Prognostic Significance of TILs in HER2+ Metastatic Breast Cancer
- • Real-World Consensus on Treating HR+/HER2- Metastatic Breast Cancer
- • Animal Models in Metastatic Breast Cancer Immunotherapy Research
- • PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders
